Moderna, Inc. — Director's Dealing 2020

Dec 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-12-14

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-14	Common Stock	M	10000	$20.93	Acquired	10000	Direct
2020-12-14	Common Stock	M	34	$14.22	Acquired	10034	Direct
2020-12-14	Common Stock	M	5000	$12.21	Acquired	15034	Direct
2020-12-14	Common Stock	M	10000	$19.15	Acquired	25034	Direct
2020-12-14	Common Stock	S	1402	$154.25	Disposed	23632	Direct
2020-12-14	Common Stock	S	3733	$155.16	Disposed	19899	Direct
2020-12-14	Common Stock	S	4922	$156.27	Disposed	14977	Direct
2020-12-14	Common Stock	S	5509	$157.17	Disposed	9468	Direct
2020-12-14	Common Stock	S	1000	$158.35	Disposed	8468	Direct
2020-12-14	Common Stock	S	2358	$159.73	Disposed	6110	Direct
2020-12-14	Common Stock	S	2907	$160.58	Disposed	3203	Direct
2020-12-14	Common Stock	S	2502	$161.65	Disposed	701	Direct
2020-12-14	Common Stock	S	701	$162.63	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-14	Stock Option (Right to Buy)	$20.93	M	10000	Disposed	2029-03-08	Common Stock (10000)	Direct
2020-12-14	Stock Option (Right to Buy)	$14.22	M	34	Disposed	2028-02-28	Common Stock (34)	Direct
2020-12-14	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-10-03	Common Stock (5000)	Direct
2020-12-14	Stock Option (Right to Buy)	$19.15	M	10000	Disposed	2026-08-10	Common Stock (10000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.67 to $154.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.68 to $155.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.73 to $156.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.77 to $157.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.10 to $158.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.14 to $160.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.17 to $161.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.34 to $162.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.48 to $162.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F11: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

F12: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

F13: This option is fully vested and exercisable.